See more : Meritor, Inc. (MTOR) Income Statement Analysis – Financial Results
Complete financial analysis of Vanta Bioscience Limited (VANTABIO.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vanta Bioscience Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Joint-stock company Slavneft-Megionneftegas (MFGS.ME) Income Statement Analysis – Financial Results
- Marriott Vacations Worldwide Corporation (VAC) Income Statement Analysis – Financial Results
- Wallbridge Mining Company Limited (WLBMF) Income Statement Analysis – Financial Results
- China Oriental Group Company Limited (CUGCF) Income Statement Analysis – Financial Results
- Gas Arabian Services Company (9528.SR) Income Statement Analysis – Financial Results
Vanta Bioscience Limited (VANTABIO.BO)
About Vanta Bioscience Limited
Vanta Bioscience Ltd. engages in the full service preclinical contract research organization. Its services include Discovery Toxicology, Agro-Chemicals and Chemical Safety, Biocompatibility Studies, Diet Formulation and Batch Release Test. The company was founded on April 29, 2016 and is headquartered in Hyderabad, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 97.23M | 58.29M | 93.94M | 98.16M | 137.54M | 120.80M | 38.77M |
| Cost of Revenue | 90.11M | 71.62M | 47.98M | 46.61M | 75.35M | 53.44M | 26.80M |
| Gross Profit | 7.12M | -13.33M | 45.96M | 51.54M | 62.19M | 67.37M | 11.97M |
| Gross Profit Ratio | 7.32% | -22.88% | 48.93% | 52.51% | 45.21% | 55.77% | 30.87% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 7.70M | 2.63M | 2.59M | 1.91M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 29.16M | 31.25K | 117.58K | 165.84K | 0.00 | 0.00 |
| SG&A | 38.96M | 36.86M | 23.41M | 23.80M | 30.31M | 37.02M | 6.19M |
| Other Expenses | 0.00 | -446.59K | -1.02M | -260.29K | -70.01K | -192.92K | -277.46K |
| Operating Expenses | 38.96M | 37.31M | 24.44M | 24.06M | 30.38M | 37.21M | 6.47M |
| Cost & Expenses | 128.87M | 108.93M | 72.42M | 70.68M | 105.74M | 90.65M | 33.27M |
| Interest Income | 0.00 | 593.83K | 776.52K | -78.14K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 57.49M | 58.86M | 23.47M | 21.32M | 19.48M | 16.89M | 1.96M |
| Depreciation & Amortization | 44.97M | 26.70M | 13.16M | 12.51M | 11.89M | 7.11M | 5.72M |
| EBITDA | 14.19M | -17.07M | 38.91M | 39.72M | 44.79M | 35.03M | 10.84M |
| EBITDA Ratio | 14.60% | -41.07% | 36.92% | 40.74% | 31.77% | 30.85% | 28.95% |
| Operating Income | -31.84M | -50.64M | 21.52M | 27.48M | 31.80M | 30.15M | 5.50M |
| Operating Income Ratio | -32.75% | -86.88% | 22.91% | 27.99% | 23.12% | 24.96% | 14.19% |
| Total Other Income/Expenses | -56.43M | -51.99M | -19.24M | -21.59M | -18.38M | -19.12M | -2.35M |
| Income Before Tax | -88.27M | -102.63M | 2.28M | 5.89M | 13.42M | 11.03M | 3.15M |
| Income Before Tax Ratio | -90.78% | -176.07% | 2.43% | 6.00% | 9.76% | 9.13% | 8.12% |
| Income Tax Expense | -2.20M | 1.82M | 936.95K | 1.41M | 3.29M | 4.05M | 2.88M |
| Net Income | -23.16M | -64.81M | 882.07K | 4.50M | 10.05M | 6.96M | 272.93K |
| Net Income Ratio | -23.82% | -111.18% | 0.94% | 4.58% | 7.30% | 5.77% | 0.70% |
| EPS | -3.67 | -10.27 | 0.14 | 0.71 | 1.59 | 1.10 | 0.05 |
| EPS Diluted | -3.67 | -10.27 | 0.14 | 0.71 | 1.59 | 1.10 | 0.05 |
| Weighted Avg Shares Out | 6.31M | 6.31M | 6.31M | 6.31M | 6.31M | 6.31M | 5.73M |
| Weighted Avg Shares Out (Dil) | 6.31M | 6.31M | 6.31M | 6.31M | 6.31M | 6.31M | 5.73M |
Source: https://incomestatements.info
Category: Stock Reports